

**AMENDMENTS TO THE SPECIFICATION**

**In the specification:**

Please replace the paragraph at page 24, lines 18-20, with the following paragraph:

--FIG. 1 shows the base sequence of DNA encoding the polypeptide (human type) of the present invention obtained in Example 2 (SEQ ID NO: 2), and the amino acid sequence (SEQ ID NO: 1) deduced from the base sequence.--

Please replace the paragraph at page 24, lines 23-25, with the following paragraph:

--FIG. 3 shows the base sequence of DNA encoding the polypeptide (human type) of the present invention obtained in Example 3 (SEQ ID NO: 9), and the amino acid sequence (SEQ ID NO: 8) deduced from the base sequence.--

Please replace the paragraph at page 24, lines 26-28, with the following paragraph:

--FIG. 4 shows the base sequence of DNA encoding the polypeptide (bovine type) of the present invention obtained in Example 4 (SEQ ID NO: 15), and the amino acid sequence (SEQ ID NO: 14) deduced from the base sequence.--

Please replace the paragraph at page 24, lines 29-31, with the following paragraph:

--FIG. 5 shows the base sequence of DNA encoding the polypeptide (rat type) of the present invention obtained in Example 5 (SEQ ID NO: 19), and the amino acid sequence (SEQ ID NO: 18) deduced from the base sequence.--

Please replace the paragraph at page 24, lines 32-33, with the following paragraph:

--FIG. 6 shows comparison of the amino acid sequences of the polypeptides of the present invention obtained in Examples 3, 4 and 5 (SEQ ID NOS: 8, 14, and 18).--

Please replace the paragraph at page 25, lines 1-3, with the following paragraph:

--FIG. 7 shows the base sequence of DNA encoding the polypeptide (mouse type) of the present invention obtained in Example 6 (SEQ ID NO: 34), and the amino acid sequence (SEQ ID NO: 33) deduced from the base sequence.--

Please replace the paragraph at page 185, lines 6-10, with the following paragraph:

-- The N-terminal amino acids of the finally purified product obtained in Example 15 were sequenced with a protein sequencer (model 491cLC; Applied Biosystems). As a result, the amino acid sequence shown by S-L-T-F-E-E-V-K-D-X-A-P-K-I-K-M-N-K-P-V- (wherein X is an unidentified amino acid residue) (SEQ ID NO: 63) was obtained.--

Please replace the paragraph at page 189, lines 4-28, with the following paragraph:

-- Human OT7T022 receptor-expressing CHO cells obtained by a modification of the method described in WO 00/29441 were inoculated on a 24-well plate in a concentration of  $3 \times 10^5$  cells/well. After incubation overnight, the cells were rinsed with Hanks' buffer (HBSS) supplemented with 0.05% BSA and 0.2 mM IBMX, and then preincubated at 37°C for 30 minutes in the same buffer. Next, the buffer was exchanged by Hanks' buffer (HBSS) supplemented with 0.05% BSA and 0.2 mM IBMX, or HBSS further added with 1  $\mu$ M forskolin only, or HBSS added with 1  $\mu$ M forskolin and peptide of various concentrations, followed by incubation at 37°C for 30 minutes. After completion of the incubation, cAMP in the cells of each well was extracted and quantified according to the method of cAMP EIA Kit (Amersham Inc.). An inhibition rate of the increased cAMP level in the cells by the forskolin treatment was calculated with the respective concentrations of the peptide. The dose-response curve as shown in FIG. 14 was obtained. The ED<sub>50</sub> levels of the peptides were hRFRP-1-12 (peptide having the 81 (Met) to 92 (Phe) amino acid sequence in SEQ ID NO: 1 (○)) (4.5 nM); hRFRP-1-37 (peptide having the 56 (Ser) to 92 (Phe) amino acid sequence in SEQ ID NO: 1 (■)) (21 nM); rRFRP-1-37 (peptide having the 58 (Ser) to 94 (Phe) amino acid sequence in SEQ ID NO: 50 (◇)) (30 nM); hRFRP-2-12 (peptide having the 101 (Phe) to 112 (Ser) amino acid sequence in SEQ ID NO: 1 (▲)); hRFRP-3-8 (peptide

having the 124 (Val) to 131 (Phe) amino acid sequence in SEQ ID NO: 1 (□)) (9.9 nM); PQRFamide (peptide shown by Pro-Gln-Arg-Phe-NH<sub>2</sub> (♦) (SEQ ID NO: 64)) (1000 nM or more); LPLRFamide (peptide shown by Leu-Pro-Leu-Arg-Phe-NH<sub>2</sub> (●) (SEQ ID NO: 65)) (36 nM); and NPFF (peptide shown by Asn-Pro-Phe-Phe (Δ) (SEQ ID NO: 66)) (140 nM), respectively. --

On page 190 of the specification, please insert the Sequence Listing submitted herewith and renumber the pages with the claims and abstract accordingly. In addition to the substitute copy of the diskette, a paper copy of the Sequence Listing is provided along with a Statement in Support of Filing and Submissions in Accordance with 37 CFR 1.821-1.825.